ストックスクリーナーアプリを入手
0.2952
2.22%
-0.0067
前日終値:
$0.3019
開ける：
$0.29
24時間の取引高:
296.31K
Relative Volume:
0.19
時価総額：
$2.97M
収益：
-
当期純損益:
$-8.26M
株価収益率:
-0.00551
EPS:
-53.609
ネットキャッシュフロー:
$-12.17M
1週間 パフォーマンス:
+19.61%
1か月 パフォーマンス:
-85.67%
6か月 パフォーマンス:
-79.92%
1年 パフォーマンス:
-97.90%
1日の値動き範囲:
$0.29
$0.305
1週間の範囲:
$0.2315
$0.3081
52週間の値動き範囲:
$0.2177
$14.45
Gri Bio Inc Stock (GRI) Company Profile
GRI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
0.2934 | 3.06M | 0 | -8.26M | -12.17M | -53.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.94 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
799.57 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
425.04 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
813.49 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.05 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-09 | 開始されました | H.C. Wainwright | Buy |
Gri Bio Inc (GRI) 最新ニュース
What drives GRI Bio Inc stock priceEarnings Forecast Updates & High Yield Trading Growth - earlytimes.in
Decliners Report: Is GRI Bio Inc stock attractive for hedge funds2025 Bull vs Bear & Free Community Consensus Stock Picks - moha.gov.vn
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
GRI Bio approves reverse stock split, stockholders vote in favor - MSN
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
GRI Bio Inc. (GRI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What technical signals suggest for GRI Bio Inc. stockEarnings Growth Report & Safe Entry Point Identification - Улправда
What insider trading reveals about GRI Bio Inc. stockLong Setup & Real-Time Buy Zone Alerts - Улправда
Why GRI Bio Inc. stock remains on buy listsWeekly Trade Analysis & Weekly Setup with High ROI Potential - Улправда
Why GRI Bio Inc. stock could be next big winnerJuly 2025 Intraday Action & Expert Approved Momentum Ideas - DonanımHaber
What sentiment indicators say about GRI Bio Inc. stockWeekly Market Outlook & Weekly Momentum Stock Picks - Улправда
Market Leaders: What Wall Street predicts for GRI Bio Inc. stock priceQuarterly Growth Report & Smart Investment Allocation Insights - Улправда
Oral therapy GRI-0621 boosts lung function, repairs tissue in IPF: Data - Pulmonary Fibrosis News
GRI Bio announces GRI-0621-IPF-02 trial met primary, secondary endpoints - MSN
GRI Bio Closes $8 Million Public Offering - The Globe and Mail
GRI Bio closes $8 million public offering of common stock and warrants - Investing.com Nigeria
GRI Bio closes $8 million public offering of common stock and warrants By Investing.com - Investing.com South Africa
GRI Bio (Nasdaq: GRI) details closing of offering, equity over $2.5M post-transaction - Stock Titan
GRI Bio Announces Closing of $8.0 Million Public Offering - GlobeNewswire
GRI Bio Launches $6.7 Million Public Offering - TipRanks
GRI Bio (NASDAQ: GRI) details $6.7M equity deal and runway into Q4 2026 - Stock Titan
GRI Bio prices $8 million public offering at $0.75 per share - Investing.com
GRI Bio announces pricing of $8M public offering - MSN
GRI Bio’s IPF drug shows positive Phase 2a results with improved lung function - Investing.com India
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
GRI Bio Announces Pricing of $8,000,000 Million Public Offering - The Manila Times
GRI Bio (NASDAQ: GRI) prices $8,000,000 offering of 10,666,667 shares at $0.75 - Stock Titan
What's Going On With GRI Bio Stock Thursday?GRI Bio (NASDAQ:GRI) - Benzinga
GRI Bio’s tazarotene achieves Phase IIa IPF success - Yahoo
GRI Bio Meets Key Goals In Phase 2 Trial Of GRI-0621 For Idiopathic Pulmonary Fibrosis - Nasdaq
GRI Bio announces positive Phase 2a trial results - MSN
GRI Bio Announces Positive Phase 2a Trial Results - TipRanks
GRI Bio, Inc. Announces Positive Phase 2a Trial Results for GRI-0621 - TradingView
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewswire
A new trading data show Milestone Pharmaceuticals Inc (MIST) is showing positive returns. - Setenews
GRI Bio (NASDAQ: GRI) updates Form S-1 with extensive warrant and contract exhibits - Stock Titan
Financial Contrast: CalciMedica (NASDAQ:CALC) and GRI Bio (NASDAQ:GRI) - Defense World
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.45% - Investing.com UK
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.45% - Investing.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
GRI Bio Reports Positive Phase 2a Trial Results - TipRanks
GRI Bio Increceives topline data from phase 2a trial for idiopathic pulmonary fibrosisSEC filing - marketscreener.com
GRI Bio Reports Positive Phase 2a Trial Results for IPF Treatment - TradingView
GRI Bio (NASDAQ: GRI) reports Phase 2a IPF topline results for GRI-0621 - Stock Titan
Ascendiant Capital Maintains GRI Bio (GRI) Buy Recommendation - Nasdaq
Ascendiant Capital Raises Price Target for GRI to $36.00 | GRI S - GuruFocus
Why GRI Bio Inc. stock is seen as undervaluedSell Signal & Weekly Return Optimization Alerts - Newser
JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025 - The Herald-Mail
GRI Bio receives Nasdaq notice for non-compliance with equity listing rule - Investing.com Australia
GRI Bio (GRI) Stock Analysis Report | Financials & Insights - Benzinga
Stop Loss: What sentiment indicators say about GRI Bio Inc. stock2025 Retail Activity & Long-Term Growth Portfolio Plans - moha.gov.vn
Gri Bio Inc (GRI) 財務データ
収益
当期純利益
現金流量
EPS
0.90%
大文字化:
|
ボリューム (24 時間):